PepGen is no longer a two-franchise neuromuscular platform. After last year's decision to stop the Duchenne program, the entire public story sits on one oligonucleotide for myotonic dystrophy type one. That concentration is the investment case and the risk in the same breath. An independent safety board just cleared the highest planned repeat-dose cohort, and the next efficacy look arrives in November. The market is not paying a commercial multiple for that setup. It is paying a cash-heavy option on whether monthly dosing can convert a striking single-dose splicing signal into a clean, placebo-controlled functional result.
Cash at midyear was $117 million, enough on the current plan into late next year. The second-quarter net loss was $18 million against a much larger year-ago print. The loss narrowed because research spending fell after the Duchenne wind-down, not because a product started to earn. The first repeat-dose cohort at the lowest strength barely separated from placebo on the headline splicing mean, and only looked better after one outlier came out. That is why November matters more than the safety board's green light. Safety clearance lets the company climb the dose ladder. It does not prove the drug works when patients receive it every month.
The unresolved partial hold from the Food and Drug Administration still keeps United States sites off the Phase two map, so the November dataset is a non-United States, small-N look. Competitors have already shown how hard a myotonia functional endpoint is to win. The question for the next several months is simple. Does the ten milligram cohort restore the dose-response seen in the single-dose study, or does repeat dosing at a still-modest strength look like another noisy, underpowered miss?